Document Detail

Tissue-engineered vascular grafts for use in the treatment of congenital heart disease: from the bench to the clinic and back again.
MedLine Citation:
PMID:  22594331     Owner:  NLM     Status:  MEDLINE    
Since the first tissue-engineered vascular graft (TEVG) was implanted in a child over a decade ago, growth in the field of vascular tissue engineering has been driven by clinical demand for improved vascular prostheses with performance and durability similar to an autologous blood vessel. Great strides were made in pediatric congenital heart surgery using the classical tissue engineering paradigm, and cell seeding of scaffolds in vitro remained the cornerstone of neotissue formation. Our second-generation bone marrow cell-seeded TEVG diverged from tissue engineering dogma with a design that induces the recipient to regenerate vascular tissue in situ. New insights suggest that neovessel development is guided by cell signals derived from both seeded cells and host inflammatory cells that infiltrate the graft. The identification of these signals and the regulatory interactions that influence cell migration, phenotype and extracellular matrix deposition during TEVG remodeling are yielding a next-generation TEVG engineered to guide neotissue regeneration without the use of seeded cells. These developments represent steady progress towards our goal of an off-the-shelf tissue-engineered vascular conduit for pediatric congenital heart surgery.
Joseph T Patterson; Thomas Gilliland; Mark W Maxfield; Spencer Church; Yuji Naito; Toshiharu Shinoka; Christopher K Breuer
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Regenerative medicine     Volume:  7     ISSN:  1746-076X     ISO Abbreviation:  Regen Med     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-05-18     Completed Date:  2012-09-12     Revised Date:  2013-06-24    
Medline Journal Info:
Nlm Unique ID:  101278116     Medline TA:  Regen Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  409-19     Citation Subset:  IM    
Interdepartmental Program in Vascular Biology & Therapeutics, Yale University School of Medicine, 333 Cedar Street Amistad 314, PO Box 208062, New Haven, CT 06520-8062, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Vessel Prosthesis*
Clinical Trials as Topic
Heart Defects, Congenital / therapy*
Neovascularization, Physiologic
Translational Medical Research*
Grant Support
5401HL098228-03/HL/NHLBI NIH HHS; 5K08HL083980-05/HL/NHLBI NIH HHS; K08 HL083980/HL/NHLBI NIH HHS; R01 HL098228/HL/NHLBI NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cellular replacement and regenerative medicine therapies in ischemic stroke.
Next Document:  Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): stu...